contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

EQL Pharma

April - JuneConsolidated sales for the first quarter amounted to SEK 10.7 (6.7) million, an increase of 58%.Gross profit for the quarter amounted to SEK 5.9 (3.9) million, an increase of 54%...

<hl2>April - June</hl2><ul><li>Consolidated sales for the first quarter amounted to SEK 10.7 (6.7) million, an increase of 58%.</li><li>Gross profit for the quarter amounted to SEK 5.9 (3.9) million, an increase of 54%.</li><li>EBITDA for the period amounted to SEK 0.9 (0.1) million.</li><li>Earnings per share were 0:00 (-0:01) SEK for the quarter.</li><li>Cash and cash equivalents was SEK 3.5 (21.2) million at the end of the period.</li></ul><hl2>Significant events during the first quarter of</hl2><ul><li>During the first quarter, the drug Prednisolon EQL Pharma has been approved for sale by the Swedish Medicines Agency. Prednisolone EQL Pharma is used in conditions requiring attenuation of the body's inflammatory reactions such as rheumatoid arthritis, asthma and other allergic diseases, ulcerative colitis and in cancer treatment. In the Nordic region, the Swedish market is the largest with about 25 MSEK in annual sales. There are only a few competitors in the Nordic region.</li><li>On May 1st, Eletriptan was launched on the Danish market. Eletriptan EQL Pharma belongs to a group of drugs called selective serotonin (5HT1) receptor agonists. Eletriptan is used in adults to treat migraine headache, with or without aura. The total turnover in Sweden and Denmark is approximately SEK 15 million annually. Currently, only the original Relpax (Pfizer) is available on the market in Sweden. In the Danish market there are two generic competitors in addition to the original.</li><li>In end of June Acetazolamide EQL Pharma was approved for sale by the Swedish Medicines Agency. The product is expected to be launched around the turn of the year 2018/2019.  Acetazolamide EQL Pharma is used as a short-term treatment for eye surgery when there is a risk of increased pressure in the eye. Acetazolamide EQL Pharma is also used as an add-on therapy for the treatment of green starr (glaucoma) and before surgery of acute narrow-angle glaucoma. The drug is a niche generic, where EQL Pharma becomes the only and first generic on the Swedish market for more than 60 years. The product is small with about SEK 2.5 million in total annual sales on the Swedish market.</li></ul>